CCNE1 and neoplasm: A composite biomarker signature incorporating low Rb score (defined as <1% tumor cells with positive nuclear staining on immunohistochemistry), high cyclin E1 (defined as ≥10% tumor cells with positive nuclear staining on immunohistochemistry), and ESR1 mutation was associated with poorer PFS (Albanell et al., 2023).